Loading workspace…
signed outSign in
Every requirement in bioskepsis-insights-user-requirements-v1.1.md, with the verdict the document’s own rules force. No requirement now carries the verdict BLOCKED. Each row carries both halves of its account, what is buildable and what is still held, and names the decisions that released it. A requirement answered the other way is DROPPED, and that is the one verdict nobody can go and change.
Showing the requirements whose account names OQ-14. Of the 21 shown, its answer released 21.
| ID | Verdict | Basis | What that means |
|---|---|---|---|
FR-TREND-01 | BUILD | stated | All of it. Every input it needed is now stated. The accelerating designation reads the OQ-06 topic score rather than a raw question count, so 'asked more and more often' is a movement in that score. A trend is shown only when at least 8 different people stand behind it, and every displayed count is rounded to the nearest 5 (OQ-14). Time is the ISO week of a question and nothing finer (OQ-43). Topics are coded with OncoTree, HGNC, HGVS with ClinGen Allele Registry IDs, and ChEMBL, with the code list version stored on every signal (OQ-44). Research Workspace questions feed these aggregates and never a named expert (OQ-07). Still held. Nothing. Two bounds travel with it rather than holding it: the 8-person minimum and the rounding apply in every view, export, alert and API answer, not only on screen, and the differencing check of NP-10 refuses an export or an API answer whose comparison could reveal a count the minimum was meant to hide. |
FR-TREND-05 | BUILD | stated | All of it, under the two minimums and the anonymity the answers set. A field signal is shown when at least 8 distinct people stand behind it (OQ-14) and, where it comes from OncoSkepsis, at least 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12). Counts are rounded to the nearest 5. Nobody is named: a pharma user sees an anonymous card, and an identity is revealed only when the expert or clinician accepts a contact request, which is stored as a consent record naming the company and the wording shown (OQ-05, OQ-42). Still held. Nothing. Below either minimum there is nothing to show, and the view says so, naming the minimum rather than rendering an empty result that reads as a quiet field. |
FR-PROF-02 | BUILD | stated | All of it. What a pharma user sees about a named expert is settled: the anonymous card until the expert accepts a contact request, and the revealed profile after (OQ-05). Signal-derived attributes on that profile obey the same minimums as everywhere else, 8 contributors and, for anything from OncoSkepsis, 3 institutions with the dominance check (OQ-14, OQ-40). Still held. Nothing. The link between a card and a real person stays inside the signal layer, and no service outside it may read that link: the reveal is a consent record, not a lookup. |
FR-ALERT-01 | BUILD | research | All of it, on the channels the answer names: a weekly email digest per user, and alerts written into the customer's CRM as tasks, for Veeva Vault CRM, Salesforce Life Sciences Cloud and IQVIA OCE (OQ-22, OQ-26). Subscriptions were already buildable; what was missing was where an alert goes and how often, and both are now stated rather than chosen here. Still held. Nothing. Every alert carries the same suppression as the view it came from: the 8-person minimum, the 3-institution minimum with the dominance check, counts rounded to 5, and nobody named without an accepted contact request (OQ-14, OQ-40, OQ-05). An alert is a delivery channel, not an exemption. |
FR-ALERT-02 | BUILD | stated | All of it. The trigger is the OQ-06 topic score crossing the NP-15 cut-off, the top 1.4 percent within a disease area, rather than a question count nobody stated. Delivery is the weekly digest and the CRM task of OQ-22. What the alert may say is bounded by the same minimums as any other view, and it names no expert who has not accepted a contact request (OQ-05, OQ-14, OQ-42). Still held. Nothing. The cut-off is configuration, because the validation study of OQ-27 replaces it with a measured one, and an alert threshold that needed a release to change is a threshold nobody will tune. |
X-01 | BUILD | inference | The cancer type named in a question, coded with OncoTree, whose code list version is stored on every signal (OQ-44). Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-02 | BUILD | inference | The gene named in a question, as an HGNC symbol (OQ-44), confirmed on 18/09/2026. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-03 | BUILD | inference | The tumour variant named in a question, in HGVS notation with a ClinGen Allele Registry ID (OQ-44). A variant-level signal is shown only above both minimums and rolls up to the gene otherwise (OQ-41), which is the whole of the re-identification control here. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-04 | BUILD | inference | The drug, drug class or mechanism named in a question, coded with ChEMBL (OQ-44). ChEMBL is CC BY-SA 3.0, so anything derived from it that this product shares travels under the same licence. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-05 | BUILD | inference | The question type, from the six OncoSkepsis functions: tumour-board case, variant interpretation, tumour-board brief, country-specific literature, reimbursement dossier and clinical-trial search (OQ-45, NP-13). Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-06 | BUILD | inference | The country of the contributing clinician, which is what makes a country facet possible without a named person behind it. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-08 | BUILD | inference | The contributing clinician's professional role, from the list OQ-10 states, confirmed on 18/09/2026. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-09 | BUILD | inference | The evidence status of the answer, as contested evidence or thin evidence, confirmed on 18/09/2026. These two flags are what the research-gap view is built from (NP-07), which is why the field exists at all. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-10 | BUILD | inference | The counts themselves: questions, distinct contributing clinicians and distinct contributing institutions, which are what the two minimums are measured against. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-11 | BUILD | inference | The change in question counts between two periods, confirmed on 18/09/2026 and governed by NP-10. Comparing two tables can reveal a small number even when each table separately meets the threshold, so the differencing check stands in front of every export and API answer, and an in-app view shows a warning instead. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-14 | BUILD | inference | Reimbursement-dossier requests, as group counts by drug and country and never per hospital (OQ-45). Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-15 | BUILD | inference | Clinical-trial search activity, as group counts by cancer type and country (OQ-45). The search that produces it is built inside OncoSkepsis on ClinicalTrials.gov and the EU trial portal (NP-13). Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
XFER-09 | BUILD | inference | All of it, confirmed by OQ-40, which supplies both numbers: an OncoSkepsis signal is shown only when at least 3 institutions stand behind it and no single institution dominates, where dominance is the count minus the two largest institutional contributions falling under 5 percent of the largest (NP-12). The 8-person minimum of OQ-14 applies on top. Still held. Nothing. p is held in configuration, so a site that needs a stricter rule sets one rather than patching a literal. |
XFER-10 | BUILD | research | All of it, on the strength NP-10 chose: a comparison that could reveal a hidden count blocks the export or the API answer outright, and an in-app view shows a warning instead. The check runs before every export and every API answer rather than at the point the data is stored. Still held. Nothing. The asymmetry is deliberate: an export leaves the building and cannot be recalled, while an in-app view is read by a signed-in user whose access is logged. |
DATA-03 | BUILD | stated | All of it. The dashboard receives aggregated signals, and the two numbers that define 'aggregated' are now stated: at least 8 distinct people behind anything shown, with displayed counts rounded to the nearest 5 (OQ-14), and at least 3 distinct institutions with the 5 percent dominance check for anything from OncoSkepsis (OQ-40, NP-12). The thresholds apply in every view, export, alert and API answer, and the differencing check refuses an output whose comparison could reveal a count they hide (NP-10). Still held. Nothing. Individual-level data does not cross at all, which OQ-05 settles: the anonymous card is what a pharma user sees, and a name arrives only through the expert's own acceptance. |
NFR-03 | BUILD | inference | All of it, confirmed by OQ-14, which supplies the number it needed: at least 8 distinct people behind anything shown, with counts rounded to the nearest 5, in every view, export, alert and API answer. Still held. Nothing. NP-01 adds an operational consequence rather than a gate: OncoSkepsis signals stay hidden until a third hospital joins, so an empty OncoSkepsis view names the minimum instead of implying a quiet field. |